Pre-clinical mRNA platform company with novel immunotherapy target with worldwide IP. Initial pediatric indication with ~$160 MM priority review voucher to be followed with large adult sold cancer market ($2BN in 5 years). World-class leadership/advisors. Merlin has LOIs of $2.5M and now has a term sheet from an investor.